Displaying 701 - 720 of 853
| Active Ingredient | EMPAGLIFLOZIN|METFORMIN |
| Therapeutic Class | SODIUM GLUCOSE CO TRANSPORTER INHIBITOR |
| Indications | Indicated as adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM) when treatment with both empagliflozin and metformin is appropriate |
| Caution | Lactic acidosis is a metabolic complication that can occur due to metformin accumulation during treatment and is fatal in ~50% of cases. Necrotizing fasciitis of the perineum (Fournier gangrene) repor More ... |
| Dose Range |
Take twice daily with meals (ie, divide total daily dose into 2 doses/day) For additional glycemic control, empagliflozin may be increased to maximum total daily dose of 25 mg in patients tolerating 10 mg/day and metformin may be increased to maximum total daily dose of 2,000 mg/day, with gradual escalation to reduce gastrointestinal adverse reactions with metformin. |
| Drug Interactions | |
| Pregnancy | Not recommended during second and third trimester of pregnancy based on animal d More ... |
| Breast Feeding | There is no information regarding presence in human milk, the effects on breastf More ... |
| Active Ingredient | GLIBENCLAMIDE |
| Therapeutic Class | SULPHONYLUREAS |
| Indications |
Diabetes Mellitus. More potent than chlorpropamide but shorter acting and not affected by renal failure. Half-life: 10 hours; Duration of Action: 24 hours. Glyburide is the micronised form More ... |
| Caution | Hypoglycemia: Occurs more commonly in elderly patients, even with low doses. It is best avoided in the elderly . c.f. prescribing in liver and renal disease p. 14; 30. |
| Dose Range |
2.5-5mg to a maximum of 20mg daily . Take with breakfast. See BDS supply protocols pg. 7. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | GLICLAZIDE |
| Therapeutic Class | SULPHONYLUREAS |
| Indications | Treatment of diabetes mellitus. May be of benefit in retinopathy. |
| Caution | Gastro intestinal upset, nausea, hypoglycemia, weight gain, dizziness. c.f. prescribing in liver and renal disease p. 14; 30. |
| Dose Range |
Intial dose: 40- 80 mg daily with breakfast, gradually increasing to 320 mg daily . Doses of more than 160 mg daily are given in 2 divided doses. M odified-release: initial dose is 30 mg once daily , increasing if necessary in step s of |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | GLIMEPIRIDE |
| Therapeutic Class | SULPHONYLUREAS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | GLYBURIDE |
| Therapeutic Class | SULPHONYLUREAS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | PIOGLITAZONE |
| Therapeutic Class | THIAZOLIDINEDIONES |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | GLUCAGON |
| Therapeutic Class | ANTIHYPOGLYCEMIC AGENTS |
| Indications | Diabetic hypoglycaemia |
| Caution | Nausea, Vomiting,Abdominal pain; hypertension; hypotension; tachycardia. |
| Dose Range |
Child 1 month–8 years (body-weight up to 25 kg) 500 micrograms, if no response within 10 minutes intravenous glucose must be given. Child 9–17 years (body-weight 25 kg and above) 1 mg, if no response within 10 minutes intravenous glucose must be given. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | DESMOPRESSIN |
| Therapeutic Class | PITUITARY |
| Indications | Diagnosis and treatment of cranial diabetes insipidus, in the treatment of nocturnal enuresis, management of mild or moderate haemophilia and type I von Willebrand's disease. |
| Caution | Fluid retention; headache; hyponatraemia. |
| Dose Range | Adult: Cranial diabetes insip idus: initial dose 100 micrograms three times daily. maintenance doses, 100 and 200 micrograms three times daily. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | VASOPRESSIN |
| Therapeutic Class | PITUITARY |
| Indications | Diabetes insipidus; post -operative abdominal distention. |
| Caution | Vascular disease, chronic nephritis, vertigo. |
| Dose Range |
s.c. or i.m. 5-10 units every 3-4 hours. i.v. 20 units over 15 minutes. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | SOMATROPIN |
| Therapeutic Class | SOMATROPHIN AGONIST |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | HYDROXYPROGESTERONE |
| Therapeutic Class | PROGESTINS |
| Indications | Amenorrhea, pre-term labour (prophylaxis). |
| Caution | Changes in appetite or weight, fluid retention, oedema, acne, chloasma (melasma), allergic skin rashes. |
| Dose Range |
Pre-term labour (prophylaxis): 250-500mg intramuscularly weekly during first half of pregnancy or longer. Amenorrhea: 375mg intramuscularly . |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | MEDROXYPROGESTERONE |
| Therapeutic Class | PROGESTINS |
| Indications |
Anovulatory dysfunctional uterin e bleeding (DUB), post menopausal hormone replacement therapy, contraception, carcinoma of the endometrium. |
| Caution | Fluid retention, menstrual disorders. Use with caution in conditions which worsen fluid retention. c.f. prescribing in liver disease p. 15. |
| Dose Range |
Oral: 2.5-10mg daily for at least 10 day s p er month as HRT; daily from day s 16 or 21 of cycle for 5-10 days in anovulatory DUB. Higher p arenteral doses are required in endometrical cancer. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | NORETHISTERONE |
| Therapeutic Class | PROGESTINS |
| Indications | See Medroxy progesterone Acetate. |
| Caution | c.f. prescribing in liver disease p. 15. Contraindicated in pregnancy . Ten times more potent than medroxy progesterone. |
| Dose Range |
Dysfunctional Uterine Bleeding: 1-2 tab. Daily for 6-12 days. To prevent relapse, 1-2 tab daily from 16th-25th day of cycle, combined with oestrogen if necessary . Endometriosis: 1 tab. Daily from 5th- 25th day of cycle for 6 mth or ½ tab. Daily , continu |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | THYROXINE |
| Therapeutic Class | THYROID AGENTS |
| Indications | Hypothyroidism. |
| Caution | Angina, sweating, headache, diarrhoea, tachycardia (features of thyrotoxicosis), weight loss, restlessness. |
| Dose Range |
50-100mcgs daily increased by 25-50mcg at intervals of about 4 weeks. Maintenance Dose: 100-200mcgs daily. Best taken on an empty stomach Start at low dose (12.5-50mcg daily ) in elderly or patients with ischaemic heart disease. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | CARBIMAZOLE |
| Therapeutic Class | ANTI-THYROID AGENTS |
| Indications | Hyperthyroidism. |
| Caution | Monitor carefully in pregnancy and breast feeding as overdose may cause fetal and neonatal thyroid depression. May cause skin rashes, joint swelling, arthalgias. |
| Dose Range |
Adult: 15- 40 mg (up to 60 mg) daily in divided doses until patient is euthyroid. Maintenance dose 5 to 15 mg daily , as a single dose. Pediatric: 0.75 mg/kg (max.30 mg) daily as single or divided doses. 12-18 y rs: 30mg daily initially , in single or div |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | PROPYLTHIOURACIL |
| Therapeutic Class | ANTI-THYROID AGENTS |
| Indications | Hyperthyroidism. |
| Caution | Fever, leukopenia, rash. |
| Dose Range |
Adult: 200-400 mg daily (600-1200 mg in severe cases) in single or divided doses until euthyroid. Maintenance dose: 50-150 mg daily . Paediatric: neonates: 2.5-5 mg/kg twice daily ; 1 month to 1 yr: 2.5 mg/kg 3 times daily : 1- 18y rs: 25 -100mg 3 tim |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ADRENALINE | LIDOCAINE |
| Therapeutic Class | LOCAL ANESTHETICS |
| Indications | Adrenaline is often added to local anaesthetics to retard diffusion and limit absorption, to prolong the duration of effect, and to lessen the danger of toxicity . |
| Caution | Protect from light. |
| Dose Range | The content of adrenaline does not exceed 0.002% (1 in 50 000). |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | BUPIVACAINE |
| Therapeutic Class | LOCAL ANESTHETICS |
| Indications |
Used in epidural analgesia. Especially in obstetrics. Contraindicated in intraveneous regional anesthesia (Bier's block). 0.75% solution is contra-indicated for epidural block in obstetrics. |
| Caution | Highly toxic effects include convulsions, respiratory and cardiac arrest in overdose. |
| Dose Range | Maximum dose of 150-175mg in a 4 hour period. High therapeutic index. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | LIDOCAINE |
| Therapeutic Class | LOCAL ANESTHETICS |
| Indications | Class I. Treatment of ventricular arrythmias complicating acute myocardial infarction. It is the most widely used of the local anesthetic agents and is used for local blocks, spinal anesth More ... |
| Caution |
Hypotension, dizziness, blurred vision, sweating, confusion, fits. Accumulates to toxic levels rapidly in patients with cardiac failure. Highly toxic effects include convulsions, respiratory More ... |
| Dose Range |
Available in concentrations from 0.5%-10%. The latter is widely used as a surface analgesic for mucous membranes. Maximum dose 4mg/kg or 250mg in 6 hours. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | LIDOCAINE | PRILOCAINE |
| Therapeutic Class | LOCAL ANESTHETICS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |